Makers of EZorb and Marvlix
 

EZorb®

 
 

Maturitas 2002 Feb 26;41(2):149-156

 

Risk of calcium oxalate nephrolithiasis in postmenopausal women supplemented with calcium or combined calcium and estrogen.

 

Domrongkitchaiporn S, Ongphiphadhanakul B, Stitchantrakul W, Chansirikarn S, Puavilai G, Rajatanavin R.

Department of Medicine, Ramathibodi Hospital, Mahidol University, Rama 6, 10400, Bangkok, Thailand

 

Background: Recent studies showed that postmenopausal women lost less bone mass when supplemented with calcium or estrogen therapy. However, the safety of the treatments in terms of the risk of calcium oxalate stone formation is unknown. We therefore conducted this study to determine the alteration in calcium oxalate supersaturation after calcium supplement or after combined calcium and estrogen therapy in postmenopausal osteoporotic women.

 

Methods: Fifty-six postmenopausal women were enrolled in this study. All subjects were more than 10 years postmenopausal with vertebral or femoral osteoporosis by bone mineral density criteria. They were randomly allocated to receive either 625 mg of calcium carbonate (250 mg of elemental calcium) at the end of a meal three times a day (group A, n=26) or calcium carbonate in the same manner plus 0.625 mg/day of conjugated equine estrogen and 5 mg medrogestone acetate from day 1--12 each month (group B, n=30). The age (mean[plus minus]S.E.M.) was 66.3[plus minus]1.2 and 65.1[plus minus]1.1 years, weight 54.1[plus minus]1.2 and 55.3[plus minus]2.1 kg, in group A and group B, respectively. Urine specimens (24-h) were collected at baseline and 3 months after treatment for the determination of calcium oxalate saturation by using Tiselius's index (AP(CaOx)) and calcium/citrate ratio.

 

Results: After 3 months of treatment, there was no significant alteration from baseline for urinary excretion of calcium, citrate and oxalate. Urinary phosphate excretion was significantly reduced (6.3[plus minus]0.7 vs. 5.1[plus minus]0.7 mmol/day for group A and 8.2[plus minus]0.9 vs. 5.8[plus minus]0.7 mmol/day for group B, P<0.05), whereas net alkaline absorption was significantly elevated (10.1[plus minus]3.6 vs. 20.1[plus minus]4.4 meq/day for group A and 4.8[plus minus]3.2 vs. 19.9[plus minus]3.6 meq/day for group B, P<0.05). Calcium/citrate ratio and AP(CaOx) determined at baseline were not different from the corresponding values after treatment in both groups; calcium/citrate: 10.1[plus minus]3.1 vs. 10.1[plus minus]2.5 for group A and 9.3[plus minus]1.8 vs. 11.9[plus minus]2.5 for group B and AP(CaOx): 1.1[plus minus]0.1 vs. 1.3[plus minus]0.2 for group A and 1.2[plus minus]0.2 vs. 1.1[plus minus]0.1 for group B. There were eight and nine patients with high AP(CaOx), or >2, at baseline and after treatment, respectively.

 

Conclusions: Calcium supplement with a meal or combined calcium supplement and estrogen therapy is not associated with a significant increased risk of calcium oxalate stone formation in the majority of postmenopausal osteoporotic patients. Determination of urinary saturation for calcium oxalate after calcium and estrogen supplements, especially at the initial phase of treatment, may be helpful in the avoidance of nephrolithiasis.

 

 

 

Osteoporosis - Comparison of Treatment Options

Compare EZorb Calcium with Osteoporosis Prescription Drugs

Bone and Joint Overview

Clinical Studies

The Importance of Collagen for Bone and Joint Health

Causes of Osteoarthritis

Treatment of Osteoarthritis - Review of Various Options

Is Rheumatoid Arthritis (RA) Really an Autoimmune Disease?

Breaking the Vicious Circle of Fibromyalgia

Bone Spur - A Natural Approach

Do You Suffer from Heel Spurs?

Juvenile Rheumatoid Arthritis

Quick EZorb Calcium Osteoporosis Facts

 

Ready to order? Go directly to our online store, or call 1-800-395-5715. Open 24 hours a day, 7 days a week. You may also use the mail order form to mail us your order.

 

 

 

 

Copyright © 2017 Elixir Industry. All Rights Reserved.